Latest Health News

Fiducian Group’s subsidiary Fiducian Investment Management Services Limited has filed a defence after ASIC initiated civil proceedings alleging misleading disclosure and compliance failures related to a managed fund.

CTI Logistics Limited anticipates a significant 55% increase in profit before tax for the half year ending December 2025, driven by robust revenue growth and operational improvements in Western Australia.

4DMedical has gained Canadian regulatory approval for its innovative CT – VQ™ ventilation-perfusion imaging technology, enabling immediate commercial rollout through Philips and expanding its North American footprint.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

Imricor Medical Systems has secured Institutional Review Board approval for the University of Virginia Health to join its VISABL-AFL clinical trial, marking a key expansion in the US. Procedures are set to begin early next year, supporting Imricor’s progress toward FDA approval and commercialisation.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.

Echo IQ has formally lodged its FDA 510(k) submission for EchoSolv HF, an AI-driven heart failure diagnostic software validated by Mayo Clinic data, aiming to tap into a $60 billion US market.

Apiam Animal Health Limited shareholders are set to vote on a scheme of arrangement offering $0.87 cash per share or a mix of cash and unlisted scrip in a new holding company controlled by Adamantem Capital. The Independent Expert deems the cash offer fair and reasonable, while scrip options carry liquidity and minority risks.

Korab Resources Limited reported a positive cash flow for the December 2024 quarter, maintaining a strong liquidity position with funding to support its exploration activities for over 17 quarters.

Artrya Limited has begun generating fee-per-scan revenues from its Salix Coronary Plaque module at Tanner Health in the U.S., marking a key commercial milestone for the AI-powered cardiac imaging platform.

HITIQ has secured a prestigious grant from the Australian Sports Commission to enhance its PROTEQT™ brain health monitoring technology, positioning the company for wider adoption across elite and community sports.

MPR Australia Limited has been suspended from ASX trading following the disposal of its main undertaking, with the exchange citing insufficient ongoing operations to justify continued quotation.